Cite
MLA Citation
Lin Lin et al.. “A phase I study of FCN-411, a pan-HER inhibitor, in EGFR-mutated advanced NSCLC after progression on EGFR tyrosine kinase inhibitors.” Lung cancer, vol. 166, 2022, pp. 98–106. http://access.bl.uk/ark:/81055/vdc_100153733642.0x000047